Platelet Hyperreactivity to Aspirin and Stroke "PLARAS"


Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- Consecutive patients with the diagnosis of ischemic stroke in the acute phase who will be treated with aspirin for an indefinite period

Exclusion Criteria

- The need for full anticoagulation therapy for pulmonary embolism, deep vein thrombosis, chronic atrial fibrillation, thrombus in the left atrium or left ventricle, or for any other reason deemed relevant by the patient's physician
- Thrombolytic treatment for stroke
- History of allergy to aspirin (hives, swelling of glottis or anaphylaxis)
- Risk of excessive bleeding due to active peptic ulcers, liver failure, history of bleeding or bleeding diathesis
- Scheduled major or vascular surgery
- Metastatic cancer or survival estimated at less than a year
- Creatinine clearance below 30 mL/min
- Platelet count <100,000/mm3
- Hematocrit <30%
- Lipaemic blood
- Difficult follow-up: patients with serious social problems, alcoholics, and residents of other states in the country
- Refusal to participate in the study